Standing Order
Novo Nordisk A/S

Dashboard

Novo Nordisk A/S

NVONYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$126B
Price$37.8252w $35.29 – $81.05
Conviction4/ 5
Revenue (TTM)$48.9B
Revenue growth YoY+5.7%
P/E (trailing)7.6
Gross margin80.8%
Operating margin42.4%
Net margin33.9%
52w price change-48.1%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 19
    Trial readoutClinicalTrials.gov

    Phase 2 trial NCT06409130 of NNC0194-0499, cagrilintide and semaglutide in alcohol-related liver disease completed.

  • Nov 19
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT06065540 of CagriSema vs semaglutide/cagrilintide/placebo in T2D completed.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Novo Nordisk posts Phase 1 trial NCT07944118 (NOT_YET_RECRUITING) examining Zenagamtide fasting and dosing effects on gastric emptying in overweight/obese T2D/非

  • Nov 18
    OtherClinicalTrials.gov

    Update on NCT07739901 Korean real-world MASLD/MASH outcomes study; sponsor Novo Nordisk; status ACTIVE_NOT_RECRUITING as of 2026-11-18.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 1 trial NCT07940582 (NNC0721-5186) in overweight/obese women listed as not yet recruiting.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Phase 1/2 trial NCT07940803 initiated for NNC0662-3168 in weight management and Type 2 diabetes (not yet recruiting).

  • Nov 17
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07845578 recruiting: high-dose s.c. semaglutide effect on gastric emptying in excess body weight subjects.

  • Nov 16
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT06588504 for dasiglucagon vs glucagon in hypoglycemia completed (Japan, T1D adults/adolescents)

  • Nov 16
    OtherClinicalTrials.gov

    Phase 3 trial NCT07220759 (cagrilintide, overweight/obesity + T2D) status updated to ACTIVE_NOT_RECRUITING.

  • Nov 16
    OtherSEC

    Form 6-K foreign issuer report filed.

  • Nov 16
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT04775082 (SCALE KIDS) for weight management in children with obesity updated to ACTIVE_NOT_RECRUITING status.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07931573 (AMBITION 3) for Zenagamtide vs semaglutide in T2D, status NOT_YET_RECRUITING.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07931495 of Zenagamtide in Type 2 diabetes, status NOT_YET_RECRUITING.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07931599 initiated (NOT_YET_RECRUITING) comparing Zenagamtide vs semaglutide in T2D patients on metformin/SGLT2i.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07931547 of Zenagamtide in Type 2 diabetes with CKD, not yet recruiting.

  • Nov 10
    OtherClinicalTrials.gov

    Phase 3 trial NCT07400107 (NNC0487-0111 vs semaglutide, weight loss/T2D) status updated to ACTIVE_NOT_RECRUITING.

  • Nov 10
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07587710 recruiting for NNC0487-0111 PK in hepatic impairment vs normal liver function

  • Nov 10
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07896109 for NNC9836-0001 safety in healthy and Type 2 diabetes participants now recruiting.

  • Nov 9
    OtherSEC

    Novo Nordisk A/S filed Form 6-K with the SEC on 2026-11-09.

  • Nov 6
    OtherClinicalTrials.gov

    Phase 3 trial NCT07533175 (NNC0487-0111, obesity + T2D) status updated to ACTIVE_NOT_RECRUITING

Not financial advice — research and opinion only. Disclosures